Skip to content
City PM
  • Germany
  • France
  • Europe
  • Markets
  • Business
  • Opinion
  • Germany
  • France
  • Europe
  • Markets
  • Business
  • Opinion
Friday 21 October 2005 10:47 am  |  Updated:  Wednesday 13 October 2021 11:02 am

Judge only trial for drug cartel

By: City PM Reporter

Add as a preferred source on Google

The Serious Fraud Office (SFO) may delay bringing criminal charges against drug company directors accused of rigging the prices of NHS drugs until next year.


The delay would allow the suspected cartelists to be tried under the new judge-only court procedure.

The SFO opened an investigation into generic drug manufacturers Goldshield Group, Generics UK, Kent Pharmaceuticals, Regent-GM Laboratories, Norton Healthcare and Ranbaxy UK almost four years ago and the police have since interviewed 16 executives.

Sources close to the companies say that the SFO has indicated charges may now be delayed until February.

The directors, who are on unconditional police bail, must attend interviews with the SFO on 6 December, but it is thought they will not actually be charged until next year.

It is not known whether the SFO intends to use the new judge-only procedure, but some of the directors involved fear it might.

A Department of Constitutional Affairs spokesman confirmed that the judge-only trials mechanism could be in place by January or February.

The government is planning to do away with jury trials in complex serious fraud cases by statutory instrument. The change requires a yes vote in the Commons and the Lords.

A spokesperson for the Law Society, which opposes judge-only trials, said that suspects could be prosecuted under the new procedure as long as they have not been charged before it is put in place.

The government has been keen to replace jury trials since the collapse of the Jubilee Line fraud case earlier this year. The SFO refused to comment on the case as it is the subject of an ongoing inquiry.

Read more

Regulator wins decade-long pricing tussle with Pfizer

Hikma reported a jump in profit for 2024

Share this article

  • Facebook
  • X
  • LinkedIn
  • WhatsApp
  • Email

Similarly tagged content:

Sections

  • News

Categories

  • Business

Trending Articles

  • Why sport fans got bored of influencers and forced brands into a mind shift

  • House of the Dragon’s Abubakar Salim dreams of Kenyan kebabs for his last supper

  • Heatwave fans demand for aircon stocks

  • Could The Billingsgate Roman Bathhouse win a Toast award?

  • Lessons in comms from my children’s primary school

More from City PM

  • Regulator wins decade-long pricing tussle with Pfizer

    Legal
    Hikma reported a jump in profit for 2024
  • Alkermes Announces Orphan Drug Designations for Alixorexton in the U.S. and Europe

    Business Wire
  • City trader: ‘My coke dealer came to the Canary Wharf office every day at 9am’

    Video
    Skyline of Canada financial district with modern skyscrapers and historic landmarks under a clear blue sky
  • CRH elects W. Anthony (Tony) Will to its Board of Directors

    Business Wire
  • 100 candles in the wind: Celebrating Marilyn Monroe’s centenary

    Life&Style
    Marilyn Monroe posing in an iconic white dress, capturing her timeless elegance and classic Hollywood glamor.
  • GSK says AI is reshaping drug pipeline as Nuvalent deal hits shares

    Tech
    GSK said total sales fell by two per cent in the third quarter
  • Two solicitors linked to Post Office scandal charged with misconduct

    Legal
    One contract was even an extension of the Horizon deal with the Post Office itself, worth £63m.
  • GSK shares slip after buying US cancer treatment firm Nuvalent for $10.6bn

    Pharma
    GSK logo displayed prominently, signifying the companys presence and relevance in the business and healthcare sectors.

City PM — European politics, business and analysis.

Europe

  • Germany
  • France
  • Europe
  • UK & Ireland

Topics

  • Business
  • Markets
  • AI
  • Technology
  • Opinion
  • Energy

More

  • Politics
  • Economics
  • Fintech
  • Legal
  • Sport
  • Life

Company

  • About City PM
  • Contact
  • Terms of Use
  • Privacy Policy
  • Cookie Policy
© 2026 City PM. All rights reserved.
About · Contact · Terms · Privacy